throbber
Paper 1
`Filed: February 19, 2019
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
` ____________
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`v.
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owner
`____________
`
`Case No. IPR2019-00686
`U.S. Patent No. 9,211,253
` ____________
`
`PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 9,211,253
`AS OBVIOUS OVER WANG
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`
`TABLE OF CONTENTS
`INTRODUCTION ............................................................................................... 1 
`I. 
`II.  IPR REQUIREMENTS UNDER 37 C.F.R. § 42.104 ........................................ 2 
`A.  Grounds for Standing Under 37 C.F.R. § 42.104(a) ..................................... 2 
`B. 
`Identification of Challenge Under 37 C.F.R. § 42.104(b) ............................ 2 
`1. 
`Statutory Grounds of Challenge ................................................................. 3 
`2. 
`Statement of Non-Redundancy .................................................................. 3 
`3.  Relief Requested ........................................................................................ 5 
`C.  Mandatory Notices Under 37 C.F.R. § 42.8 ................................................. 5 
`1.  Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8(b)(1) ......................... 5 
`2.  Related Matters Under 37 C.F.R. § 42.8(b)(2) .......................................... 6 
`Identification of Lead and Back-Up Counsel Under 37 C.F.R. §
`3. 
`42.8(b)(3)............................................................................................................. 6 
`4. 
`Service Information Under 37 C.F.R. § 42.8(b)(4) .................................... 7 
`III.  LEVEL OF ORDINARY SKILL IN THE ART .............................................. 7 
`IV.  OVERVIEW OF THE ’253 PATENT ............................................................. 9 
`A.  Summary of the Specification ....................................................................... 9 
`B. 
`Summary of the Claims ............................................................................... 10 
`C. 
`Summary of Relevant Portions of the File History ..................................... 10 
`D.  The ’253 Patent Lacks Priority to the Filing Date of the ’379 Provisional.
`
`11 
`V.  BACKGROUND AND OVERVIEW OF TECHNOLOGY ............................ 13 
`A.  A POSA Would Have Been Motivated to Develop Improved Intranasal
`Naloxone Formulations to Combat the Opioid Epidemic. ................................... 13 
`B.  A POSA Would Have Had the Know-How to Readily Develop an
`Improved Intranasal Naloxone Formulation. ....................................................... 16 
`The volume of the nasal cavity naturally limits the volume of a naloxone
`1. 
`nasal spray to about 100 µL per spray. ............................................................. 17 
`2.  A POSA would have been motivated to use a 4-6 mg naloxone dose to
`achieve desirable naloxone exposure levels. .................................................... 18 
`
`i
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`3.  A POSA would have had adequate know-how and ability to select
`commonplace excipients to make a stable, well-tolerated intranasal naloxone
`formulation. ....................................................................................................... 19 
`4.  A POSA would have been motivated to load an intranasal naloxone
`formulation into an easy-to-use single-dose, pre-primed nasal sprayer. .......... 21 
`VI.  CLAIM CONSTRUCTION UNDER 37 C.F.R. § 42.104(b)(3) ................... 22 
`A. 
`“pre-primed” ................................................................................................ 22 
`B. 
`“patient” ....................................................................................................... 23 
`C. 
`“delivery time” ............................................................................................ 23 
`D. 
`“90% confidence interval for dose delivered per actuation is ±about 2.0%”
`and “95% confidence interval for dose delivered per actuation is
`±about 2.5%” ........................................................................................................ 23 
`VII.  SUMMARY OF THE PRIOR ART ............................................................... 24 
`A.  Wang (Chinese Patent Publication CN 1575795) ....................................... 24 
`B.  Additional References ................................................................................. 25 
`C. 
`Public Accessibility of the April 12, 2012 FDA Materials ......................... 26 
`VIII.  THE CHALLENGED CLAIMS ARE UNPATENTABLE ....................... 28 
`A.  Ground 1: Claims 1–7, 12–14, and 16 are obvious over Wang (Nalox1008),
`Djupesland (Nalox1010), HPE (Nalox1012), Bahal (Nalox1014), and Kushwaha
`(Nalox1013). ......................................................................................................... 28 
`1.  Claim 1 ..................................................................................................... 28 
`2.  Claim 2 ..................................................................................................... 36 
`3.  Claim 3 ..................................................................................................... 37 
`4.  Claim 4 ..................................................................................................... 40 
`5.  Claim 5 ..................................................................................................... 40 
`6.  Claim 6 ..................................................................................................... 41 
`7.  Claim 7 ..................................................................................................... 41 
`8.  Claims 12–14 ............................................................................................ 42 
`9.  Claim 16 ................................................................................................... 43 
`B.  Ground 2: Claims 10–11 and 17–29 are obvious over Wang (Nalox1008),
`Djupesland (Nalox1010), HPE (Nalox1012), Bahal (Nalox1014), Kushwaha
`(Nalox1013), and Wyse (Nalox1007). ................................................................. 44 
`
`ii
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`1.  Claims 10 and 11 ...................................................................................... 44 
`2.  Claims 17 and 18 ...................................................................................... 45 
`3.  Claim 19 ................................................................................................... 46 
`4.  Claims 20–23 ............................................................................................ 47 
`5.  Claim 24 ................................................................................................... 49 
`6.  Claims 25–29 ............................................................................................ 49 
`C.  Ground 3: Claim 15 is obvious over Wang (Nalox1008), Djupesland
`(Nalox1010), HPE (Nalox1012), Bahal (Nalox1014), Kushwaha (Nalox1013),
`and Wyse (Nalox1007) or Wermeling 2013 (Nalox1016) or Pharmacologist
`POSA knowledge. ................................................................................................ 51 
`D.  Ground 4: Claims 8 and 9 are obvious over Wang (Nalox1008),
`Djupesland (Nalox1010), HPE (Nalox1012), Bahal (Nalox1014), Kushwaha
`(Nalox1013), and the ’291 Patent (Nalox1015). .................................................. 54 
`IX.  SECONDARY CONSIDERATIONS ............................................................ 56 
`A.  No teaching away ........................................................................................ 56 
`B.  No commercial success ............................................................................... 60 
`C.  No long-felt but unmet need or failure of others ......................................... 60 
`D.  No unexpected superior results ................................................................... 61 
`X.  CONCLUSION ................................................................................................. 62 
`
`
`
`
`
`iii
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`TABLE OF EXHIBITS
`
`Description
`Exhibit No.
`Nalox1001 U.S. Patent No. 9,211,253 (the ’253 patent)
`Nalox1002
`Expert Declaration of Maureen Donovan
`Nalox1003
`
`Expert Declaration of Günther Hochhaus
`Excerpt of File History of U.S. Patent No. 9,561,177, Aug. 22,
`2016 Office Action, Non-Final Rejection (Aug. 22, 2016 Non-
`Final Rejection)
`Excerpt of File History of U.S. Patent No. 9,561,177, Oct. 21, 2016
`Amendment and Response to Office Action (Oct. 21, 2016
`Response to Office Action)
`Excerpt of File History of U.S. Patent No. 9,561,177, Dec. 21, 2016
`Office Action, Notice of Allowance and Fees Due (Notice of
`Allowance)
`Nalox1007 U.S. Patent No. 9,192,570 (Wyse)
`Nalox1008
`Chinese Patent No. 1,575,795 (Wang)
`Nalox1009
`
`PCT International App. Pub. No. WO00/62757 (Davies)
`Djupesland, P., Nasal Drug Delivery Device: Characteristics and
`Performance in a Clinical Perspective - A Review, 3 Drug Deliv.
`& Transl. Res. 42–62 (2013) (Djupesland)
`Grassin-Delyle, S. et al., Intranasal Drug Delivery: An Efficient
`and Non-invasive Route for Systemic Administration, Focus on
`Opioids, 134 Pharm. & Ther. 366–79 (2012) (Grassin-Delyle)
`Handbook of Pharmaceutical Excipients, 56–60, 64–66, 78–81,
`220–22, 242–44, 270-72, 441–45, 517–22, 596–98 (Rowe, R. et al.
`eds., 6th ed. 2009) (HPE)
`Nalox1013 Kushwaha, S. et al., Advances in Nasal Trans-Mucosal Drug
`Delivery, (1)7 J. Applied Pharm. Sci. 21–28 (2011) (Kushwaha)
`Nalox1014 U.S. Patent No. 5,866,154 (Bahal)
`Nalox1015 U.S. Patent No. 8,198,291 (the ’291 patent)
`
`Nalox1004
`
`Nalox1005
`
`Nalox1006
`
`Nalox1010
`
`Nalox1011
`
`Nalox1012
`
`iv
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`
`Nalox1016
`
`Nalox1018
`
`Nalox1019
`
`Nalox1020
`
`Nalox1021
`
`Exhibit No.
`
`Description
`Wermeling, D., A Response to the Opioid Overdose Epidemic:
`Naloxone Nasal Spray, 3 Drug Deliv. & Transl. Res. 63–74 (2013)
`(Wermeling 2013)
`Nalox1017 Alabama Department of Public Health, Alabama EMS Patient
`Care Protocols (7th ed., Oct. 2013) (Alabama EMS Protocols)
`Aptar Pharma, Press Release, Aptar Pharma Provides Unit-Dose
`Nasal Spray Technology for Treatment of Opioid Overdose (Apr.
`20, 2016) (Aptar Press Release)
`Ashton, H. et al., Best Evidence Topic Report Intranasal Naloxone
`in Suspected Opioid Overdose, 23(3) Emerg. Med. J. 221–23
`(2006) (Ashton)
`Barton, E. et al., Intranasal Administration of Naloxone by
`Paramedics, 6 Prehosp. Em. Care 54–58 (Barton 2002)
`Barton, E. et al., Efficacy of Intranasal Naloxone as a Needleless
`Alternative for Treatment of Opioid Overdose in the Prehospital
`Setting, 29(3) J. Emerg. Med. 265–71 (2005) (Barton 2005)
`Bitter, C. et al., Nasal Drug Delivery in Humans, 40 Curr. Probl.
`Dermatol. 20–35 (2011) (Bitter)
`Boyer, E., Management of Opioid Analgesic Overdose, 367(2) N.
`Engl. J. Med. 146–55 (2012) (Boyer)
`CDC, NDA No.
`21-450 Clinical Pharmacology &
`Biopharmaceutics Review (2002) (Zomig Review)
`Excerpt of Commonwealth of Kentucky, Kentucky Patient Care
`Protocols (Mar. 13, 2015) (Kentucky Patient Care Protocols)
`Costantino, H. et al., Intranasal Delivery: Physiochemical and
`Therapeutic Aspects, 337 Int’l. J. of Pharm. 1–24 (2007)
`(Constantino)
`Dowling, J. et al., Population Pharmacokinetics of Intravenous,
`Intramuscular, and Intranasal Naloxone in Human Volunteers,
`30(4) Ther. Drug. Monit. 490–96 (2008) (Dowling)
`FDA, Center for Drug Evaluation and Research, Guidance for
`Industry, Nasal Spray and Inhalation Solution, Suspension, and
`Spray Drug Products – Chemistry, Manufacturing, and Controls
`Documentation (2002) (2002 FDA Guidance)
`
`Nalox1022
`
`Nalox1023
`
`Nalox1024
`
`Nalox1025
`
`Nalox1026
`
`Nalox1027
`
`Nalox1028
`
`v
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`
`Nalox1029
`
`Nalox1030
`
`Nalox1031
`
`Nalox1034
`
`Exhibit No.
`
`Description
`FDA, Center for Drug Evaluation and Research, Guidance for
`Industry, Bioavailability and Bioequivalence Studies for Nasal
`Aerosols and Nasal Sprays for Local Action (2003) (2003 FDA
`Guidance)
`Freise, K. et al., Naloxone Reversal of an Overdose of a Novel,
`Long-Acting Transdermal Fentanyl Solution
`in Laboratory
`Beagles, 35(2) J. Vet. Pharmacol. Therap. 45–51 (2012) (Freise)
`Glende, O., Development of non-injectable naloxone for pre-
`hospital reversal of opioid overdose: A Norwegian project and a
`review of international status (May 2016) (unpublished M.A.
`thesis, Norwegian University of Science and Technology) (on file
`with Norwegian University of Science and Technology) (Glende)
`Nalox1032 Hertz, S., Naloxone for Outpatient Use: Data Required to Support
`an NDA, PowerPoint Presentation (Hertz Presentation)
`Nalox1033
`Intentionally left blank
`Kelly, A-M. et al., Randomised Trial of Intranasal Versus
`Intramuscular Naloxone in Prehospital Treatment for Suspected
`Opioid Overdose, 182(1) Med. J. Austl. 24–27 (2005) (Kelly)
`Nalox1035 Kerr, D. et al., Intranasal Naloxone for the Treatment of Suspected
`Heroin Overdose, 103 Addiction 379–86 (2008) (Kerr 2008)
`Kerr, D. et al., Randomized Controlled Trial Comparing the
`Effectiveness & Safety of Intranasal & Intramuscular Naloxone for
`the Treatment of Suspected Heroin Overdose, 104 Addiction 2067–
`74 (2009) (Kerr 2009)
`Kleiman-Wexler, R. et al., Pharmacokinetics of Naloxone-An
`Insight into the Locus of Effect on Stress-Ulceration, 251(2) J.
`Pharmacol. Exp. Ther. 435–38 (1989) (Kleiman-Wexler)
`Marple, B. et al., Safety Review of Benzalkonium Chloride Used as
`a Preservative in Intranasal Solutions: An Overview of Conflicting
`Data and Opinions, 130 Otolaryngol Head Neck Surg. 131–41
`(2004) (Marple)
`Nalox1039 Merck Index, Isotonic Solutions, MISC-47–69 (Windholz, M. et al.
`eds., 10th ed. 1983) (Merck Index)
`Merlin, M. et al., Intranasal Naloxone Delivery is an Alternative to
`Intravenous Naloxone for Opioid Overdoses, 28 Am. J. Emerg.
`Med. 296–303 (2010) (Merlin)
`
`Nalox1036
`
`Nalox1037
`
`Nalox1038
`
`Nalox1040
`
`vi
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`
`Exhibit No.
`
`Nalox1041
`
`Nalox1042
`
`Nalox1043
`
`Nalox1044
`
`Nalox1045
`
`Nalox1046
`
`Nalox1047
`
`Nalox1048
`
`Nalox1049
`
`Nalox1050
`
`Nalox1051
`
`Nalox1052
`
`Description
`Middleton, L. et al., The Pharmacodynamic & Pharmacokinetic
`Profile
`of
`Intranasal
`Crushed
`Buprenorphine &
`Buprenorphine/Naloxone Tablets in Opioid Abusers, 106(8)
`Addiction 1460–73 (2011) (Middleton)
`Monitto, C. et al., The Optimal Dose of Prophylactic Intravenous
`Naloxone in Ameliorating Opioid-Induced Side Effects in Children
`Receiving Intravenous Patient-Controlled Analgesia Morphine for
`Moderate to Severe Pain: A Dose Finding Study, 113(4)
`Anesthesia & Analgesia 834–42 (2011) (Monitto)
`Pharmacodynamic Agents, in Foye’s Principles of Medicinal
`Chemistry, 670 (Lemke, T. et al. eds., 6th ed. 2008) (Lemke)
`Physicians’ Desk Reference, NARCAN [Naloxone Hydrochloride
`Injection, USP], IMITREX Nasal Spray [Sumatriptan], 1300–02,
`1546–50 (57th ed., 2003) (PDR 2003)
`Physicians’ Desk Reference, ZOMIG Nasal Spray [Zolmitriptan],
`768–78 (64th ed., 2010) (PDR 2010)
`Robertson, T. et al., Intranasal Versus Intravenous Naloxone for
`Prehospital Narcotic Overdose, Abstract, 12(5)(1) Acad. Emerg.
`Med. 166–67 (2005) (Robertson 2005)
`Robertson, T. et al., Intranasal Naloxone is a Viable Alternative to
`Intravenous Naloxone for Prehospital Narcotic Overdose, 13
`Prehosp. Emerg. Care 512–15 (2009) (Robertson 2009)
`Role of Naloxone in Opioid Overdose Fatality Prevention; Public
`Workshop; Request for Comments, 76 Fed. Reg. 71,348 (Nov. 17,
`2011) (Role of Naloxone Fed. Reg. Notice)
`Role of Naloxone in Opioid Overdose Fatality Prevention FDA
`Meeting Transcript (Apr. 12, 2012) (2012 FDA Meeting)
`Rosanske, T., Morphine, in Chemical Stability of Pharmaceuticals:
`A Handbook for Pharmacists, 604–11 (Connors, K. et al. eds., 2d
`ed. 1986) (Rosanske)
`Sabzghabaee, A. et al., Naloxone Therapy in Opioid Overdose
`Patients: Intranasal or Intravenous? A Randomized Clinical Trial,
`10(2) Arch. Med. Sci. 309–14 (2014) (Sabzghabaee)
`Intentionally left blank
`
`vii
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`
`Nalox1053
`
`Nalox1059
`
`Nalox1060
`
`Exhibit No.
`
`Description
`Trows, S. et al., Analytical Challenges and Regulatory
`Requirements for Nasal Drug Products in Europe and the U.S., 6
`Pharm. 195–219 (2014) (Trows)
`Nalox1054 United States Pharmacopeia and National Formulary (USP 36-NF
`31) Vol 1., 54–55, 930–33 (2013) (USP)
`Nalox1055 U.S. Patent Appl. No. 61/918,802 (the ’802 Appl.)
`Nalox1056 U.S. Patent No. 5,307,953 (’953 patent)
`Nalox1057 U.S. Patent No. 5,813,570 (’570 patent)
`Nalox1058 U.S. Provisional Patent Appl. No. 61/953,379 (the ’379
`provisional)
`Wermeling, D., Opioid Harm Reduction Strategies: Focus on
`Expanded Access to Intranasal Naloxone, 30(7) Pharmacotherapy
`627–31 (2010) (Wermeling 2010)
`Loimer, N. et al, Nasal Administration of Naloxone is as Effective
`as the Intravenous Route in Opiate Addicts, 29(6) Int’l J. of
`Addictions 819–27 (1994) (Loimer)
`Doe-Simkins, M. et al., Saved by
`the Nose: Bystander-
`Administered Intranasal Naloxone Hydrochloride for Opioid
`Overdose, 99(5) Am. J. Pub. Health 788–91 (2009)
`McDermott, C. & Collins, N., Prehospital Medication
`Administration: A Randomised Study Comparing Intranasal and
`Intravenous Routes, Em. Med. Int’l. 1–5 (2012)
`Nalox1063
`Intentionally left blank.
`Nalox1064 Authenticating Affidavit of Christopher Butler (“Butler Affidavit”)
`Nalox1065 Authenticating Affidavits of Rachel J. Watters
`Nalox1066 Authenticating Affidavit of Pamela Lipscomb
`
`Nalox1061
`
`Nalox1062
`
`viii
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`INTRODUCTION
`Nalox-1 Pharmaceuticals, LLC (“Petitioner”) respectfully petitions for inter
`
`I.
`
`partes Review (“IPR”) of claims 1–29 (the “Challenged Claims”) of U.S. Patent No.
`
`9,211,253 (“the ’253 patent”), purportedly owned by Opiant Pharmaceuticals, Inc.
`
`(“Patent Owner”). Nalox1001. For the reasons addressed below, the Challenged
`
`Claims should be found unpatentable and canceled.
`
`The ’253 patent is listed in the FDA’s Approved Drug Products with
`
`Therapeutic Equivalence Evaluations (a.k.a. “The Orange Book”) as covering
`
`intranasal naloxone sold under the Narcan® name. Naloxone rapidly reverses opioid
`
`overdose – it is an opioid antagonist and acts to restore normal respiration to a person
`
`whose breathing is impaired from opioid overdose. Naloxone has been available
`
`since 1971 as an injection, and its intranasal administration has been known in the
`
`community since at least 1994 as a safe and effective opiate overdose treatment.
`
`Loimer (Nalox1060) at 819. Narcan® is currently the only FDA-approved single-
`
`use nasal spray indicated for the emergency treatment of known or suspected opioid
`
`overdose. Because of the Patent Owner’s listing of patents in The Orange Book,
`
`there are currently no generic versions of intranasal Narcan® on the market. Patent
`
`Owner’s disingenuous use and abuse of the patent system here is contrary to the
`
`Constitution’s requirement to “promote the progress of science and useful arts” by
`
`wrongfully monopolizing access to life-saving medicine until 2035, based on
`
`1
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`generations-old science and the most obvious applications in this art.
`
`The United States is in the throes of an opioid epidemic. According to the
`
`Centers for Disease Control and Prevention, on average, 130 Americans die each
`
`day from an opioid overdose, and in 2017, the number of overdose deaths involving
`
`opioids was six times higher than in 1999. There is a critical and urgent need in
`
`America for intranasal naloxone products intended for community use and which
`
`can be deployed in life-threatening circumstances – often by people who are not
`
`medically trained. America cannot afford to wait another day for affordable, safe,
`
`and effective intranasal naloxone. The ’253 patent is a barrier wrongfully and
`
`shamefully preventing broader accessibility to this critically needed naloxone
`
`medication. Removal of the ’253 patent (and its relatives) as a barrier will save
`
`American lives by facilitating rapid and expanded access to life-saving naloxone.
`
`II.
`
`
`
`IPR REQUIREMENTS UNDER 37 C.F.R. § 42.104
`A. Grounds for Standing Under 37 C.F.R. § 42.104(a)
`Petitioner certifies that the ’253 patent is available for IPR and that Petitioner
`
`is not barred or estopped from requesting an IPR challenging the claims on the
`
`grounds identified herein.
`
`B.
`Identification of Challenge Under 37 C.F.R. § 42.104(b)
`Petitioner requests that the Patent Trial and Appeal Board (“Board”)
`
`
`
`invalidate the challenged claims of the ’253 patent for the reasons identified below.
`
`2
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`1.
`Statutory Grounds of Challenge
`Petitioner challenges claims 1–29 of the ’253 patent and requests that each
`
`claim be cancelled based on the following grounds, which are supported by the
`
`Declarations of Dr. Maureen Donovan (Nalox1002) and Dr. Günther Hochhaus
`
`(Nalox1003):
`
`Ground
`
`Claims
`
`Basis
`
`References
`
`1
`
`2
`
`3
`
`4
`
`1–7, 12–14,
`16
`
`10–11,
`17–29
`
`§103(a)
`
`§103(a)
`
`15
`
`§103(a)
`
`8–9
`
`§103(a)
`
`Wang in view of Djupesland, HPE, Bahal,
`and Kushwaha
`
`Wang in view of Djupesland, HPE, Bahal,
`Kushwaha, and Wyse
`
`Wang in view of Djupesland, HPE, Bahal,
`Kushwaha, and Wyse or Wermeling 2013
`or Pharmacologist POSA knowledge
`
`Wang in view of Djupesland, HPE, Bahal,
`Kushwaha, and the ’291 patent
`
`2.
`Statement of Non-Redundancy
`This is Petitioner’s first challenge of the ’253 patent before the Board.
`
`Petitioner submits the grounds in this Petition are not redundant nor duplicative of
`
`the grounds previously presented to the Office in the ’253 patent. In particular, Wang
`
`was never fully and substantively considered during the prosecution of the ’253
`
`3
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`patent. While cited, initialed in an Information Disclosure Statement (“IDS”), and
`
`listed on the face of the ’253 patent, a true and accurate translation of Wang was not
`
`before the Office. Instead, Applicants provided only a machine translation from
`
`Google Patents. Wang was not relied on in making any substantive rejections in
`
`the ’253 patent. In fact, the Office never rejected any claim during the prosecution
`
`of the ’253 patent.
`
`In situations where prior art, relied on in an IPR petition, was cited by Patent
`
`Owner in an IDS and nominally initialed by the Examiner, the Board has rejected
`
`Patent Owner’s arguments in denying institution by declining to invoke 35 U.S.C. §
`
`325(d). See, e.g., Fox Factory, Inc., v. SRAM, LLC, IPR2017-00472, Paper 10 at 8–
`
`9 (PTAB April 21, 2017); Digital Check Corp. d/b/a ST Imaging v. e-Imagedata
`
`Corp., IPR2017-00178, Paper 6 at 12–13 (PTAB April 25, 2017); Limelight
`
`Networks, Inc. v. Mass. Inst. of Tech., IPR2017-00249, Paper 9 at 7 (PTAB May 18,
`
`2017); Microsoft Corp. v. Parallel Networks Licensing, LLC, IPR2015-00486, Paper
`
`10 at 15 (PTAB July 15, 2015). Therefore, recognizing that the Board has discretion,
`
`Petitioner respectfully requests the Board not invoke 35 U.S.C. § 325(d), because
`
`Wang was merely listed in an IDS, provided as a machine-translated English version,
`
`and initialed by the Examiner, without substantive discussion of the reference.
`
`4
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`3.
`Relief Requested
`Petitioner requests the Board cancel the Challenged Claims as being
`
`
`
`unpatentable under AIA 35 U.S.C. § 103(a).
`
`C. Mandatory Notices Under 37 C.F.R. § 42.8
`1.
`Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8(b)(1)
`Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioner certifies that Nalox-1
`
`Pharmaceuticals, LLC, BCIM Partners III, LP, BCIM General Partner III, LP,
`
`Burford Capital Ireland DAC, BCIM PIII Holdings, LLC, Burford Capital
`
`Investment Management LLC, Burford Capital Holdings (UK) Limited, and Burford
`
`Capital Limited are the real parties in interest (collectively, “RPI”). Nalox-1
`
`Pharmaceuticals, LLC, a Delaware limited liability company, is 100% owned by
`
`BCIM Partners III, LP, a Delaware limited partnership. BCIM General Partner III,
`
`LLC, a Delaware limited liability company, is the general partner of BCIM Partners
`
`III, LP, and Burford Capital Investment Management LLC is the investment
`
`manager to BCIM Partners III, LP. No other person has authority to direct or control
`
`(i) the timing of, filing of, content of, or any decisions or other activities relating to
`
`this Petition or (ii) any timing, future filings, content of, or any decisions or other
`
`activities relating to the future proceedings related to this Petition. All of the costs
`
`associated with this Petition are expected to be borne by Nalox-1 Pharmaceuticals,
`
`LLC, BCIM Partners III, LP, BCIM General Partner III, LP, Burford Capital
`
`5
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`Investment Management LLC and Burford Capital Holdings (UK) Limited.
`
`2.
`Related Matters Under 37 C.F.R. § 42.8(b)(2)
`Petitioner identifies the following judicial or administrative matters that
`
`would affect, or be affected by, a decision in this proceeding. Patent Owner has
`
`asserted the ’253 patent in the following United States District Court civil actions:
`
`2:18-cv-15287 (D.N.J.), 2:16-cv-07721 (D.N.J.) (consolidated). Petitioner is not a
`
`party to these actions. Petitioner is concurrently filing inter partes review petitions
`
`on related U.S. Patent Nos. 9,468,747; 9,561,177; 9,629,965; and 9,775,838, which
`
`are listed in The Orange Book as covering Narcan® nasal spray (naloxone).
`
`3.
`
`Identification of Lead and Back-Up Counsel Under 37 C.F.R.
`§ 42.8(b)(3)
`Petitioner provides the following designation of counsel:
`
`Lead Counsel
`
`Dr. Yelee Y. Kim (Reg. No. 60,088)
`Telephone: 202.857.6147
`Fax: 202.857.6395
`Yelee.Kim@arentfox.com
`
`
`
`Back-Up Counsel
`
`Janine A. Carlan (Reg. No. 42,387)
`Telephone: 202.715.8506
`Fax: 202.857.6395
`Janine.Carlan@arentfox.com
`
`Richard Berman (Reg. No. 39,107)
`Telephone: 202.857.6232
`Fax: 202.857.6395
`Richard.Berman@arentfox.com
`
`Bradford Frese (Reg. No. 69,772)
`Telephone: 202.857.6496
`Fax: 202.857.6395
`Bradford.Frese@arentfox.com
`
`
`
`6
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`
`Lead Counsel
`
`Back-Up Counsel
`
`Christopher Yaen (Reg. No. 66,563)
`Telephone: 202.350.3760
`Fax: 202.857.6395
`Christopher.Yaen@arentfox.com
`4.
`Service Information Under 37 C.F.R. § 42.8(b)(4)
`Please address all correspondence to above-identified counsel at:
`
`ARENT FOX LLP
`1717 K Street NW
`Washington D.C. 20006
`Petitioner consents to electronic service.
`
`
`
`
`
`III. LEVEL OF ORDINARY SKILL IN THE ART
`As it relates to the ’253 patent, a person of ordinary skill in the art (“POSA”)
`
`would comprise a team of individuals having experience in drug development, and
`
`specifically the development of solution-based dosage forms such as intranasal
`
`dosage forms. Donovan (Nalox1002), ¶26; see also Hochhaus (Nalox1003), ¶22.
`
`This team would include at least one formulator with experience in preformulation
`
`testing for and selection of excipients for a solution-based dosage form (including
`
`intranasal dosage forms) to achieve a target pharmaceutical profile (hereafter
`
`“Formulator POSA”). Donovan (Nalox1002), ¶26. The Formulator POSA would
`
`likely have a Ph.D. in pharmacy, pharmaceutics, pharmaceutical chemistry, or a
`
`similar field involving pharmaceutical formulations, and would have several years
`
`of experience in pharmaceutical formulation development, including development
`
`7
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`of solution-based dosage forms, including intranasal dosage forms. Id. Alternatively,
`
`such a Formulator POSA would have a Bachelor’s or Master’s degree in pharmacy,
`
`pharmaceutical chemistry, or a similar field involving pharmaceutical formulations,
`
`and would have many years of experience developing and testing pharmaceutical
`
`formulations. Id. The Formulator POSA would also have an understanding of the
`
`importance, use, and component elements of certain commercially-available
`
`delivery systems for dosage forms, including inhalers, metered-dose nasal sprayers,
`
`and single-dose nasal sprayers, as well as the importance of the properties of the
`
`spray from such devices (including droplet size and spray plume geometry). Id.
`
`The POSA team would also include drug development professionals with
`
`clinical, clinical pharmacology, and regulatory expertise relevant to the design and
`
`performance of a drug development strategy for solution-based dosage forms such
`
`as intranasal dosage forms, including testing and/or evaluating the fate of the drug
`
`in
`
`the body
`
`(i.e., pharmacokinetics,
`
`including
`
`the physiological and
`
`biopharmaceutical aspects of nasal drug absorption), testing and/or evaluating issues
`
`of safety and efficacy, and evaluating the regulatory requirements of a new dosage
`
`form. Hochhaus (Nalox1003), ¶22. Within the team, the clinical pharmacologist
`
`generally serves as a link between formulators and clinicians, and helps integrate
`
`formulation and clinical aspects of drug development. Id. Such a clinical
`
`pharmacologist would routinely collaborate with others, such as formulators and
`
`8
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`clinicians, to achieve a target pharmaceutical profile. Id.
`
`A clinical pharmacologist member of the drug development team (hereinafter
`
`a “Pharmacologist POSA”) would have an advanced degree in pharmacy, clinical
`
`pharmacology, pharmaceutics, or a similar field, and would have several years of
`
`experience in drug development, including the development of solution-based
`
`dosage forms, including nasal spray dosage forms. Hochhaus (Nalox1003), ¶23. The
`
`person would also have an understanding of drug formulation/device combinations,
`
`including the selection of excipients and their relationship to drug exposure and
`
`clinical outcomes. Id.
`
`IV. OVERVIEW OF THE ’253 PATENT
`The ’253 patent, entitled “Nasal Drug Products and Methods of Their Use,”
`
`was filed March 16, 2015, and issued on December 15, 2015 from U.S. Application
`
`No. 14/659,472 (“the ’472 Application”). The ’253 patent claims priority to U.S.
`
`Provisional Application No. 61/953,379 filed on March 14, 2014.
`
`A.
`Summary of the Specification
`The ’253 patent specification is generally directed towards naloxone drug
`
`products for nasal delivery. Nalox1001 at 1:8–12. The ’253 patent admits the
`
`maturity of naloxone (CAS Reg. No. 357-08-4), in use since at least the 1970s along
`
`with an array of published reports of naloxone’s safe and effective intranasal
`
`delivery as early as at least 1994. Id. at 2:44–47; 9:41–10:3. In particular, the ’253
`
`9
`
`

`

`IPR2019-00686
`Petition for Inter Partes Review of U.S. Patent No. 9,211,253
`patent discloses “a single-use, pre-primed device adapted for nasal delivery of a
`
`pharmaceutical composition to a patient by one actuation of the device into the
`
`nostril of the patient.” Id. at 21:5–8. These compositions can be used in methods of
`
`treating opioid overdose or suspected opioid overdose, as well as symptoms such as
`
`respiratory depression resulting from opioid overdose. See id. at 22:52–61.
`
`B.
`Summary of the Claims
`The ’253 patent includes a single independent claim and twenty eight
`
`dependent claims that depend directly or indirectly thereto. The claims of the ’253
`
`patent (recited in full in Donovan (Nalox1002), ¶¶92–94 and Hochhaus
`
`(Nalox1003), ¶¶38–39) generally relate to drug products adapted for nasal delivery
`
`comprising a single-use, pre-primed device for delivering a pharmaceutical
`
`composition comprising naloxone hydrochloride or a hydrate thereof, along with
`
`certain inactive ingredients. Nalox

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket